CODX vs. PSTV, MLSS, NEPH, WOK, ECOR, RBOT, MODD, NMTC, POCI, and TMDIF
Should you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include Plus Therapeutics (PSTV), Milestone Scientific (MLSS), Nephros (NEPH), WORK Medical Technology Group (WOK), electroCore (ECOR), Vicarious Surgical (RBOT), Modular Medical (MODD), NeuroOne Medical Technologies (NMTC), Precision Optics (POCI), and Titan Medical (TMDIF). These companies are all part of the "medical equipment" industry.
Co-Diagnostics vs. Its Competitors
Co-Diagnostics (NASDAQ:CODX) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.
Plus Therapeutics has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Co-Diagnostics currently has a consensus target price of $5.50, indicating a potential upside of 1,541.79%. Plus Therapeutics has a consensus target price of $8.88, indicating a potential upside of 1,711.22%. Given Plus Therapeutics' higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Co-Diagnostics.
In the previous week, Plus Therapeutics had 4 more articles in the media than Co-Diagnostics. MarketBeat recorded 6 mentions for Plus Therapeutics and 2 mentions for Co-Diagnostics. Plus Therapeutics' average media sentiment score of 1.19 beat Co-Diagnostics' score of -0.50 indicating that Plus Therapeutics is being referred to more favorably in the news media.
Co-Diagnostics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.
15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 8.4% of Co-Diagnostics shares are held by insiders. Comparatively, 0.8% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Plus Therapeutics has a net margin of -357.85% compared to Co-Diagnostics' net margin of -3,588.33%. Plus Therapeutics' return on equity of 0.00% beat Co-Diagnostics' return on equity.
Summary
Plus Therapeutics beats Co-Diagnostics on 11 of the 17 factors compared between the two stocks.
Get Co-Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Co-Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:CODX) was last updated on 8/29/2025 by MarketBeat.com Staff
MarketBeat All Access